Characteristics of patients initiating empagliflozin or other non-insulin glucose lowering drugs in the United Kingdom (Empa DUS in UK)

First published 22/08/2016

Last updated 14/10/2026

EU PAS number:

EUPAS14507

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

1245-0122-protocol-2016-08-11_Version 2.0_highlighted_geschwärzt

English (591.2 KB - PDF) View document

Study results

1245-0122-final-report_redacted_final

English (110.76 KB - PDF) View document

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Characteristics of patients initiating empagliflozin or other non-insulin glucose lowering drugs in the United Kingdom (Empa DUS in UK)

Secondary tabs

Share this page